Anchiano Therapeutics Announces Confidential Submission of Draft Registration Statement for U.S. Initial Public Offering

CAMBRIDGE, Mass., October 31, 2018 –  Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it has submitted on a confidential basis to the U.S. Securities and Exchange Commission (the “SEC”) a draft registration statement for a possible initial public offering in the United States of American Depositary Shares (“ADSs”) representing ordinary shares of Anchiano Therapeutics. The number and dollar amount of ADSs proposed to be offered and sold have not yet been determined.

The proposed U.S. IPO is expected to commence as market conditions permit and is subject to the public filing with the SEC of a registration statement on Form F-1, and its review and declaration of effectiveness.

This announcement is made pursuant to, and in accordance with, Rule 135 of the Securities Act of 1933. This announcement does not, and is not intended to, constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States or elsewhere, and it does not, and is not intended to, constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Company Contact:
Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
info@anchiano.com

Investor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com